Monday, November 14

7:00 am  Registration and Poster Set Up

8:00 am  Welcome
  Karl Salzwedel, NIAID

8:10 am  Keynote: Addressing HIV Persistence: A Novel Approach Involving α4β7 Integrin
  Anthony Fauci, Director, NIAID

Session 1: Martin Delaney Collaboratories for HIV Cure Research Overview
  Chairs: Carl Dieffenbach, NIAID & Michael Lederman, Case Western Reserve University

8:45 am  BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication
  Overview
  Douglas Nixon, George Washington University

  Harnessing Cytotoxic T-Lymphocytes to Eliminate Intact and Defective Viral Reservoirs
  R. Brad Jones, George Washington University

  Directing Immune Effectors to Viral Sanctuaries in Lymphoid Tissues
  Elizabeth Connick, University of Arizona

  Cure Research Community Engagement Strategies
  Manya Magnus, George Washington University

  (Additional Panelists: Tyson Evans, DC CARE and START at Westminster & Deborah Persaud, Johns Hopkins University)

9:45 am  Break (poster viewing & networking)

10:15 am  DARE: Delaney AIDS Research Enterprise to Cure HIV
  Overview of the Scientific Agenda
  Steven Deeks, University of California, San Francisco

  Breaching the B Follicular Sanctuary
  Louis Picker, Oregon Health & Science University

  Immune Checkpoint Blockade
  Sharon Lewin, The Peter Doherty Institute for Infection and Immunity

  Characterizing the Systemic Reservoir
  Timothy Henrich, University of California San Francisco

  (Additional Panelists: Jeff Lifson, Frederick National Laboratory for Cancer Research & David Evans, Project Inform)

11:15 am  defeatHIV: Delaney Cell and Genome Engineering Initiative
  Overall Scientific Strategy
  Keith Jerome, Fred Hutchinson Cancer Research Center

  Modeling Cell and Gene Therapy for HIV/AIDS in Nonhuman Primates
  Hans-Peter Kiem, Fred Hutchinson Cancer Research Center

  Constructing CAR T Cells as an Approach for HIV Therapy
  Larry Corey, Fred Hutchinson Cancer Research Center

  Paving the Road to Meaningful Engagement in HIV Cure Research
Michael Louella, University of Washington

(Additional Panelists: Deborah Fuller, University of Washington & Chris Peterson, Fred Hutchinson Cancer Research Center)

12:15 pm  Lunch (on your own)

1:15 pm  Poster Session

Session 2: Martin Delaney Collaboratories for HIV Cure Research Overview (continued)
Chairs: Richard T. D’Aquila, Northwestern University & Satya Dandekar, University of California - Davis

2:15 pm  BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy
Goals & Clinical Studies
Luis Montaner, Wistar Institute

Clonal Expansion of Latently Infected Cells as a Barrier to Cure
Robert Siliciano, Johns Hopkins University

Antibody Therapeutics
Michel Nussenzweig, The Rockefeller University

Developing HIV-Resistant and HIV-Specific T Cells
James Riley, University of Pennsylvania

(Additional Panelists: Pablo Tebas, University of Pennsylvania & David Metzger, University of Pennsylvania)

3:15 pm  Break (poster viewing & networking)

3:30 pm  CARE: Collaboratory of AIDS Researchers for Eradication
Towards Effective Latency Reversal and Viral Clearance
David Margolis, University of North Carolina, Chapel Hill

Latency Reversal: Tools and Metrics
Daria Hazuda, Merck

Antibodies as Targeting Agents for HIV-Infected Cells
Barton Haynes, Duke University

Models for HIV Cure Research
Ann Chahroudi, Emory University

(Additional Panelists: Nancie Archin, UNC Chapel Hill & Erik Valera, Latino Commission on AIDS)

4:30 pm  I4C: Combined Immunologic Approaches to Cure HIV-1
Overview
Dan Barouch, Beth Israel Deaconess Medical Center

Ad26/MVA Therapeutic Vaccination + TLR7 Stimulation in NHPs
Nelson Michael, US Military HIV Research Program

Clinical Trial Portfolio
John Mellors, University of Pittsburgh

Systems Serology to Define Immune Correlates of Viral Remission
Galit Alter, Ragon Institute

(Additional Panelists: Jintanat Ananworanich, MHRP & Sherri Karas, U. Pittsburgh [CAB])

5:30 pm  Adjourn for the Day
Tuesday, November 15
8:00 am  Registration

8:30 am  **Keynote:** Clinical Trials in HIV Cure: Where Have We Been, Where Should We Be Going?  
*Daniel Kuritzkes, Brigham and Women's Hospital*

**Session 3: Clinical Studies, Pediatrics, and Early Treatment**  
Chairs: Grace Aldrovandi, University of Southern California & Frank Maldarelli, NCI

9:00 am  HIV Cure Research in the AIDS Clinical Trials Group (ACTG): Ongoing Studies and Opportunities for Collaboration  
*Joseph Eron, University of North Carolina, Chapel Hill*  
*Rajesh Gandhi, Massachusetts General Hospital*

9:30 am  IMPAACT HIV Eradication Strategies for Pediatric Populations  
*Deborah Persaud, Johns Hopkins University*

9:45 am  Early Treatment Initiation and Treatment Interruption  
*Jintanat Ananworanich, US Military HIV Research Program*

10:00 am  Panel Discussion

10:15 am  Break (poster viewing & networking)

**Session 4: Community Engagement, Social Science, and Ethical Considerations for HIV Cure Research**  
Chairs: Amanda Castel, George Washington University & Dázon Dixon Diallo, SisterLove

10:45 am  Beyond Reservoirs and Latency: Social and Behavioral Aspects of HIV Cure  
*Judith Auerbach, University of California, San Francisco*

11:00 am  The Power of the Cure: A Personal Perspective  
*Regan Hofmann, UNAIDS*

11:15 am  HIV Cure Studies: Risk, Risk Perception, and Ethics  
*Nir Eyal, Harvard University*

11:30 am  Crowdsourcing Contests and Community Engagement for HIV Cure Research: A Mixed Methods Evaluation  
*Allison Mathews, University of North Carolina, Chapel Hill*

11:45 am  Panel Discussion

12:00 pm  Lunch (on your own)

1:00 pm  **Poster Session**

**Session 5: HIV Cure Basic Research**  
Chairs: Jonathan Kam, Case Western Reserve University & Ronald Swanstrom, University of North Carolina, Chapel Hill

2:00 pm  **NCI HIV Dynamics and Replication Program**  
Clones of HIV-Infected Cells Arise in Vivo in the First Few Weeks Following Infection  
*Stephen Hughes, NCI Center for Cancer Research*

Characterizing the Transcriptional Activity of HIV Proviruses in Blood and Tissues Collected after Long-Term ART  
*Mary Kearney, NCI Center for Cancer Research*

2:30 pm  **NIAID Vaccine Research Center**
Understanding Mechanisms of HIV Persistence using Virus Sequence Analysis in HIV Controllers  
*Eli Boritz, NIAID Vaccine Research Center*

Steady-State and Post-Vaccination TFH Dynamics in HIV Patients Treated with Combined Antiretroviral Therapy  
*Eirini Moysi, NIAID Vaccine Research Center*

3:00 pm **Abstracts Selected for Oral Presentation**

*Cells Containing Hypermutated HIV-1 Proviruses Can Be Preferentially Targeted by Cytotoxic T Lymphocytes*  
Ya-Chi Ho, Johns Hopkins University School of Medicine

*The HIV-1 Antisense Transcript Ast Recruits the Polycomb Repressor Complex 2 to the HIV-1 5'LTR and Acts as a Viral Latency Factor*  
Fabio Romerio, University of Maryland School of Medicine

3:30 pm Break (poster viewing & networking)

**Session 6: Preclinical HIV Cure Research**

*Chairs: Deborah Fuller, University of Washington & Jeffrey Lifson, Frederick National Laboratory for Cancer Research*

4:00 pm **BIDMC/OHSU Consortium for Innovative AIDS Research (CIAR) in Nonhuman Primates**  
Dan Barouch, Beth Israel Deaconess Medical Center  
Louis Picker, Oregon Health & Science University

4:30 pm **Emory Consortium for Innovative AIDS Research (CIAR) in Nonhuman Primates**  
Eric Hunter, Emory University  
Rama Amara, Emory University

5:00 pm **amfAR HIV Cure Research Institute in San Francisco**  
Structure, Directions and Partnerships  
Paul Volberding, University of California, San Francisco

5:30 pm Adjourn for the Day

**Wednesday, November 16**

8:00 am Registration

8:30 am **Keynote:** Developing T cell Therapies for HIV: Lessons from Virus-Specific T Cell Therapies Post-Transplant  
*Catherine Bollard, Children’s National Medical Center*

**Session 7: Beyond HAART: Innovative Approaches to Cure HIV-1**

*Chairs: Timothy Henrich, University of California, San Francisco and Christopher Peterson, Fred Hutchinson Cancer Research Center*

9:00 am A Gene Therapeutic Approach to Stable Suppression of HIV-1 Replication  
*Ronald Desrosiers, University of Miami*

9:30 am A Defend and Destroy Approach to Curing HIV  
*David Scadden, Massachusetts General Hospital*

10:00 am Anti-HIV Gene Therapy: Defend and Attack  
*Irvin Chen, University of California, Los Angeles*

10:30 am Break (poster viewing & networking)
11:00 am  RNA-Directed Silencing and Excision of HIV-1 and CCR5
           Kevin Morris, Beckman Research Institute of the City of Hope

11:30 am  Engineering T cells to Provide Durable Control of HIV-1 Replication
           James Riley, University of Pennsylvania

12:00 pm  Next-Generation HSC Gene Therapy for HIV Control and Eradication
           Paula Cannon, University of Southern California
           Hans-Peter Kiem, Fred Hutchinson Cancer Research Center

12:30 pm  Closing Remarks
           Karl Salzwedel, NIAID

12:45 pm  Adjourn Meeting